S

Sarcoma: adjuvant chemotherapy, systematic review and IPD meta-analysis

Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual participant data

SELPHI

SELPHI: An HIV Self-testing Public Health Intervention

SHIELD

A phase II double-blind, placebo controlled, randomised, single centre study to assess the safety, tolerability and acceptability of dextrin-2-sulphate (DS) gel in sexually active female subjects and their male sexual partners at low risk of HIV infection

SHINE

A randomised trial of therapy shortening for minimal tuberculosis with new WHO-recommended doses/fixed-dose-combination drugs in African and Indian HIV+ and HIV- children

SMART

A large, simple trial comparing two strategies for management of anti-retroviral therapy

SMILE

Strategy for Maintenance of HIV suppression with once daily integrase inhibitor +darunavir/ritonavir in children

SORCE

A multi-centre phase III double-blind placebo-controlled study designed to examine the efficacy and tolerability of sorafenib (Nexavar) in patients with resected (total or partial) primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

SPARTAC

Short Pulse Anti-Retroviral Therapy At sero-Conversion

ST02

A randomised, controlled trial of pre- and post-operative chemotherapy in patients with operable gastric and lower oesophageal cancer

ST03

A randomised phase II/III trial of perioperative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma and a feasibility study evaluating lapatinib in HER-2 positive oesophagogastric adenocarcinomas and (in selected centres) MRI and PET/CT sub-studies

STAMPEDE

Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

STAND

Shorter Treatment for Advancing Novel Drugs

START

Strategic Timing of AntiRetroviral Treatment

STOPCAP M0, bisphosphonates, systematic review and aggregate data meta-analysis

Addition of bisphosphonates to standard of care in men with localised, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

STOPCAP M0, docetaxel, systematic review and aggregate data meta-analysis

Addition of docetaxel to standard of care in men with localised hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

STOPCAP M1, abiraterone, systematic review and aggregate data meta-analysis

Addition of abiraterone to standard of care in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

STOPCAP M1, aggregate data network meta-analysis

What is the optimal systemic treatment of men with metastatic, hormone-sensitive prostate cancer? a systematic review and network meta-analyses of aggregate data

STOPCAP M1, bisphosphonates, systematic review and aggregate data meta-analysis

Addition of bisphosphonates to standard of care in men with metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

STOPCAP M1, docetaxel, systematic review and aggregate data meta-analysis

Addition of docetaxel to standard of care in men with metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

STOPCAP M1, prostate RT, systematic review and aggregate data meta-analysis

Addition of prostate radiotherapy to ADT in men with metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

STOPCAP M1 Programme

Prostate cancer: STOPCAP M1 Programme. Speeding up the evaluation of therapies for metastatic, hormone-sensitive prostate cancer

STOP-HCV-1

Stratified Treatment Optimisation for HCV-1

STREAM Stage 1

The evaluation of a standardised treatment regimen of anti-tuberculosis drugs for patients with MDR-TB

STREAM Stage 2

The Evaluation of a Standardised Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB

Study C

A randomised international multi-centre trial for the evaluation of a four-drug fixed dose combined tablet daily in the initial phase (2 months) of chemotherapy followed by a two-drug fixed dose combined tablet three times a week in the continuation phase (4 months) for the treatment of pulmonary tuberculosis.

SWET

Softened Water Eczema Trial